Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
Kensei YamaguchiYung-Jue BangSatoru IwasaNaotoshi SugimotoMin-Hee RyuDaisuke SakaiHyun Cheol ChungHiasto KawakamiHiroshi YabusakiJeeyun LeeTatsu ShimoyamaKeun-Wook LeeKaku SaitoYoshinori KawaguchiTakahiro KamioAkihito KojimaMasahiro SugiharaKohei ShitaraPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
This study provides preliminary evidence that T-DXd has clinical activity in patients with heavily pretreated HER2-low gastric/GEJ adenocarcinoma.